Oncolytics Biotech (ONCY) Projected to Post Quarterly Earnings on Wednesday

Oncolytics Biotech (NASDAQ:ONCY) is anticipated to issue its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.

Oncolytics Biotech (NASDAQ:ONCY) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.02). On average, analysts expect Oncolytics Biotech to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Oncolytics Biotech Price Performance

Shares of ONCY stock opened at $0.92 on Wednesday. The stock’s fifty day simple moving average is $1.00 and its 200 day simple moving average is $1.01. The firm has a market cap of $106.26 million, a price-to-earnings ratio of -3.16 and a beta of 1.02. Oncolytics Biotech has a one year low of $0.33 and a one year high of $1.51.

Insiders Place Their Bets

In other Oncolytics Biotech news, Director Patricia S. Andrews acquired 35,400 shares of Oncolytics Biotech stock in a transaction on Thursday, February 12th. The shares were bought at an average price of $0.86 per share, with a total value of $30,444.00. Following the completion of the purchase, the director owned 78,128 shares in the company, valued at $67,190.08. This trade represents a 82.85% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Wayne Pisano acquired 30,000 shares of Oncolytics Biotech stock in a transaction on Thursday, February 12th. The stock was acquired at an average cost of $0.84 per share, for a total transaction of $25,200.00. Following the purchase, the director owned 492,414 shares of the company’s stock, valued at approximately $413,627.76. This represents a 6.49% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 304,282 shares of company stock worth $259,232 in the last three months. Company insiders own 0.10% of the company’s stock.

Hedge Funds Weigh In On Oncolytics Biotech

Several large investors have recently made changes to their positions in the company. Citadel Advisors LLC acquired a new position in shares of Oncolytics Biotech during the third quarter valued at $535,000. XTX Topco Ltd acquired a new position in shares of Oncolytics Biotech during the fourth quarter valued at $69,000. Virtu Financial LLC acquired a new position in shares of Oncolytics Biotech during the fourth quarter valued at $68,000. Tocqueville Asset Management L.P. acquired a new position in shares of Oncolytics Biotech during the fourth quarter valued at $63,000. Finally, CIBC Private Wealth Group LLC acquired a new position in shares of Oncolytics Biotech during the fourth quarter valued at $44,000. Institutional investors and hedge funds own 6.82% of the company’s stock.

Analyst Ratings Changes

ONCY has been the topic of several recent analyst reports. Weiss Ratings lowered Oncolytics Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, April 24th. Wall Street Zen raised Oncolytics Biotech from a “strong sell” rating to a “hold” rating in a research note on Saturday, April 4th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Oncolytics Biotech presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.